Cipcal 250 Tablet is categorized as a nutritional supplement utilized mainly for addressing insufficient calcium levels in the blood. This formulation is effective in managing various health issues linked to low calcium, such as Vitamin D deficiency, osteoporosis characterized by weakened bones, hypoparathyroidism which results in inadequate calcium production by the parathyroid glands, latent tetany that manifests as muscle symptoms due to low calcium, and conditions like rickets or osteomalacia that involve the softening or distortion of bones due to calcium deficiency. Vitamin D deficiency typically arises from insufficient dietary intake, malabsorption in the intestines, or lack of adequate sunlight exposure. The active constituents of Cipcal 250 Tablet include Calcium, a vital mineral essential for the prevention and treatment of calcium deficiencies, and Cholecalciferol, a form of Vitamin D3 which plays a critical role in regulating blood levels of calcium and phosphorus while aiding in bone mineralization. This combination is beneficial for preventing and treating bone-related disorders such as rickets and osteomalacia. The dosage of Cipcal 250 Tablet will be determined by a healthcare professional based on individual health needs. Generally, this supplement is considered safe for consumption, although it may sometimes lead to minor side effects like constipation or gastrointestinal discomfort, which typically do not necessitate medical intervention and will usually resolve on their own. It is important to inform your healthcare provider if you have known allergies to Cipcal 250 Tablet or any of its components, as well as any history of heart, kidney, liver, or blood vessel disorders, kidney stones, high calcium levels, excess Vitamin D, bile deficiency, phosphate imbalance, or malabsorption syndrome prior to initiating treatment. Pregnant or nursing individuals should seek medical guidance before using this supplement. It is deemed safe for children when prescribed by a doctor.




Reviews
There are no reviews yet.